QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.105.095125v1 317/1/37    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wang, K. Articles by Penn, M. S. Search for Related Content PubMed PubMed Citation Articles by Wang, K. Articles by Penn, M. S.

CARDIOVASCULAR

Peroxisome Proliferator-Activated Receptor Down-Regulates Receptor for Advanced Glycation End Products and Inhibits Smooth Muscle Cell Proliferation in a Diabetic and Nondiabetic Rat Carotid Artery Injury Model

Departments of Cardiovascular Medicine and Cell Biology, Cleveland Clinic Foundation, Cleveland, Ohio (K.W., Z.Z., M.Z., L.F., F.F., X.Z., A.M.L., E.J.T., M.S.P.); and Department of Surgery, College of Physicians and Surgeons, Columbia University, New York, New York (W.Q., A.M.S.)

Diabetes is associated with an increase in circulating advanced glycosylation end products (AGEs) and the increased expression of the receptor for AGEs (RAGE). Inhibition of AGE/RAGE binding through the administration of soluble RAGE (sRAGE) has been shown to decrease neointimal hyperplasia. Peroxisome proliferator-activated receptor (PPAR), which inhibits neointimal hyperplasia, has been shown to decrease RAGE expression in cultured endothelial cells. We hypothesized that PPAR agonists inhibit neointimal hyperplasia via down-regulation of RAGE in vivo. Pretreatment of rat aortic smooth muscle cells (SMCs) with PPAR agonist rosiglitazone significantly down-regulated RAGE expression and inhibited SMC proliferation in response to the RAGE agonist S100/calgranulins. In vivo studies showed that rosiglitazone decreased RAGE expression and SMC proliferation at 7 days following carotid arterial injury in both diabetic and nondiabetic rats. At 21 days following injury, neointimal formation was significantly decreased in both diabetic and nondiabetic animals that received rosiglitazone. To determine whether inhibition of neointimal formation by PPAR activation could fully be accounted for by its down-regulation of RAGE, we compared the results obtained in animals treated with sRAGE, PPAR activator, and sRAGE + PPAR activator. Consistent with PPAR working through its effects on RAGE, we found that the addition of PPAR activator to sRAGE did not result in any further decrease in neointimal formation. These data demonstrate for the first time that PPAR agonists inhibit RAGE expression at sites of arterial injury and suggest that down-regulation of RAGE by the PPAR activation inhibits neointimal formation in response to arterial injury.

Address correspondence to: Dr. Kai Wang, Department of Cardiovascular Medicine F25, Cleveland Clinic Foundation, 9500 Euclid Ave., Cleveland, OH 44195. E-mail: wangk{at}ccf.org

This article has been cited by other articles:

				E. Caglayan and S. Rosenkranz Living on the Edge: Hypoxia-Induced Tissue Damage Circ. Res., April 25, 2008; 102(8): 864 - 865. [Full Text] [PDF]

				M. Joner, A. Farb, Q. Cheng, A. V. Finn, E. Acampado, A. P. Burke, K. Skorija, W. Creighton, F. D. Kolodgie, H. K. Gold, et al. Pioglitazone Inhibits In-Stent Restenosis in Atherosclerotic Rabbits by Targeting Transforming Growth Factor-{beta} and MCP-1 Arterioscler. Thromb. Vasc. Biol., January 1, 2007; 27(1): 182 - 189. [Abstract] [Full Text] [PDF]